UGT1A1
Gastrointestinal & Hepatic System · Phase I & Phase II Xenobiotic Detoxification
How does UGT1A1 help the body clear bilirubin?
UGT1A1 modifies bilirubin by attaching glucuronic acid, making it easier for the body to eliminate. Reduced enzyme function can affect bilirubin handling, but the exact variant and blood-test pattern determine its significance.
- Common Gene Name
- UDP glucuronosyltransferase family 1 member A1
- NCBI Gene ID
- 54658
- Chromosome
- 2
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (22 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Gilbert syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2012-02 | |
| Crigler-Najjar syndrome | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2012-02 | |
| Warfarin resistance | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2012-02 | |
| Belinostat | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Irinotecan | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Sacituzumab Govitecan-hziy | FDA pharmacogenetics | Management recommendation | Drug-specific subgroup | View source |
| Nilotinib | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Pazopanib | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Dolutegravir | FDA pharmacogenetics | Pharmacokinetics only | Drug-specific subgroup | View source |
| Raltegravir | FDA pharmacogenetics | Pharmacokinetics only | Drug-specific subgroup | View source |
| Arformoterol (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Pulmonary | View source |
| Belinostat | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Binimetinib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Cabotegravir and Rilpivirine (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Dolutegravir | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Indacaterol | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Pulmonary | View source |
| Irinotecan | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Nilotinib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pazopanib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Raltegravir | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Infectious Diseases | View source |
| Sacituzumab Govitecan-hziy (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Imlunestrant (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Gastrointestinal & Hepatic System